(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
The most effective method to Apply Antiquated Ways of thinking in Current Brain science Practices- Stop the ‘good’ vs ‘bad’ snap judgments and watch your world become more interesting
- Very good quality Greens All over The Planet
- What to know about new CDC deputy director who has been critical of COVID vaccines
- 'Israel has the right to continue its attacks,' Lebanese Foreign Minister announces
- Top German court to rule on claims by Wirecard shareholders
- A hospital discharged a woman in labor. This lawmaker wants change.
- Elanco's drug gets emergency nod to treat deadly flesh-eating parasite in cats
- Discussion on deployment of foreign troops ongoing, two sources tell 'Post'
